A5091485944- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Asthma and respiratory diseases
- Autoimmune and Inflammatory Disorders Research
- Cytokine Signaling Pathways and Interactions
- Rheumatoid Arthritis Research and Therapies
- Immunodeficiency and Autoimmune Disorders
- Nail Diseases and Treatments
- Spondyloarthritis Studies and Treatments
- Urticaria and Related Conditions
- Monoclonal and Polyclonal Antibodies Research
- Allergic Rhinitis and Sensitization
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Biosimilars and Bioanalytical Methods
- Complementary and Alternative Medicine Studies
- Pregnancy and Medication Impact
- Mast cells and histamine
- Therapeutic Uses of Natural Elements
- Retinoids in leukemia and cellular processes
- Autoimmune and Inflammatory Disorders
- Antifungal resistance and susceptibility
- Skin Diseases and Diabetes
Yale University
2019-2025
Central Dermatology
2019-2025
George Washington University
2023
RELX Group (United States)
2020-2023
American Academy of Dermatology
2011-2022
Oxfam
2020-2021
John Wiley & Sons (United States)
2020-2021
John Wiley & Sons (United Kingdom)
2020-2021
Hudson Institute
2020-2021
University Dermatology
2021
Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles such therapies are not well known. We compared two biologic agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) etanercept inhibitor tumor necrosis factor alpha), treatment psoriasis.We randomly assigned 903 moderate-to-severe psoriasis to receive subcutaneous injections either 45 or 90 mg (at weeks 0 4) high-dose (50 twice weekly 12 weeks). The...
Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in treatment of psoriasis.In two phase 3 (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive (210 mg or 140 every 2 weeks), ustekinumab (45 for a body weight ≤100 kg 90 >100 kg), placebo. At week 12, receiving again maintenance dose 210 weeks weeks, 4 8 weeks; continued 12 placebo received weeks. The primary aims evaluate...
For psoriasis, an idiopathic inflammatory disorder of the skin, microbial biota has not been defined using cultivation-independent methods. We used broad-range 16S rDNA PCR for archaea and bacteria to examine microbiota normal psoriatic skin. From 6 patients, 19 cutaneous samples (13 from diseased skin skin) were obtained. Extracted DNA was subjected broad range PCR, 1,925 cloned products compared with 2,038 previously reported healthy persons. Using 98% sequence identity as a species...
Psoriasis is a common chronic inflammatory disease of the skin. We sought to characterize and compare cutaneous microbiota psoriatic lesions (lesion group), unaffected contralateral skin from patients (unaffected similar loci in matched healthy controls (control group) order discern patterns that govern colonization their relationship clinical diagnosis.Using high-throughput 16S rRNA gene sequencing, we assayed bacterial communities 51 triplets characterized these samples using community...
Tofacitinib is a novel, oral Janus kinase inhibitor under investigation as potential treatment for plaque psoriasis.This Phase 2b, 12-week, dose-ranging study (A3921047, NCT00678210) aimed to characterize the exposure-response, efficacy and safety of tofacitinib vs. placebo in patients with moderate-to-severe chronic psoriasis.One hundred ninety-seven were randomized. The primary endpoint was proportion achieving ≥ 75% reduction Psoriasis Area Severity Index (PASI 75) score at week 12.At 12,...
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy safety of bimekizumab as compared with secukinumab, which alone, in patients moderate-to-severe plaque psoriasis have not been extensively examined.
Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well determine eligibility criteria clinical studies. However, owing the heterogeneity of classifications and their lack consideration impact psoriasis involvement special areas or past history, patients may be miscategorized, which can lead undertreatment psoriasis.To develop a consensus statement on classification severity.A modified Delphi approach was developed by International Council...
BackgroundDeucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits cytokine signaling in psoriasis pathogenesis.ObjectiveThe objective of this study was to demonstrate deucravacitinib superiority versus placebo and apremilast moderate severe plaque based on ≥75% reduction from baseline Psoriasis Area Severity Index a static Physician's Global Assessment score 0 (clear) or 1 (almost clear) with ≥2-point improvement at week 16.MethodsPOETYK second trial...
Tapinarof cream is a topical aryl hydrocarbon receptor-modulating agent under investigation for the treatment of psoriasis. modulates expression interleukin-17 and skin-barrier proteins filaggrin loricrin.We conducted two identical phase 3 randomized trials tapinarof in patients with mild-to-severe plaque Adults baseline Physician's Global Assessment (PGA) score 2 (mild) to 4 (severe) (on scale from 0 4, higher scores indicating more severe psoriasis) percent total body-surface area affected...